Targets › PARP3
9 programs from 9 companies in 217 trials: 102 Phase 2, 85 Phase 1, 24 Phase 3, 6 Phase 4; Oncology, Other, Genitourinary; next expected readout Nov 2026.
Mono-ADP-ribosyltransferase that mediates mono-ADP-ribosylation of target proteins and plays a key role in the response to DNA damage. Mediates mono-ADP-ribosylation of glutamate, aspartate or lysine residues on target proteins. (UniProt, Q9Y6F1)
Open in Phaseline: the race on PARP3, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| AstraZeneca | Olaparib PARP 1, 2 and 3 inhibitor | PARP1, PARP3, PARP2 | Phase 4 | Metastatic Castration-resistant Prostate Cancer; Advanced Ovarian Cancer; Platinum Sensitive; Endometrial Neoplasms … | Nov 2026 |
| M.D. Anderson Cancer Center | [18F]-4FN PARP 1, 2 and 3 inhibitor | PARP1, PARP3, PARP2, CHRNB2, CHRNA4, Tubulin, OPRM1, CD274 | Phase 4 | Lymphoma; Tobacco Use Cessation; Cigarette Smoking-Related Carcinoma; Hematopoietic and Lymphoid Cell Neoplasm … | Dec 2026 |
| Alliance for Clinical Trials in Oncology | Rucaparib camsylate PARP 1, 2 and 3 inhibitor | PARP1, PARP3, PARP2 | Phase 3 | Castration-Resistant Prostate Carcinoma | Mar 2027 |
| The Netherlands Cancer Institute | ddAC-CP-Olaparib PARP 1, 2 and 3 inhibitor | PARP1, PARP2, PARP3 | Phase 3 | Breast Cancer; Cancer; Ovarian Cancer | May 2027 |
| Merck & Co. (MSD) | Olaparib PARP 1, 2 and 3 inhibitor | PARP1, PARP3, PARP2 | Phase 3 | Lung Neoplasms; Small Cell Lung Cancer; Solid Tumors; Advanced Solid Neoplasms … | May 2027 |
| pharmaand | Rucaparib PARP 1, 2 and 3 inhibitor | PARP1, PARP3, PARP2 | Phase 3 | Epithelial Ovarian Cancer; Leiomyosarcoma; Peritoneal Cancer; Adenocarcinoma of the Oesophagus … | Dec 2030 |
| National Cancer Institute (NCI) | Veliparib PARP 1, 2 and 3 inhibitor | PARP1, PARP3, PARP2 | Phase 2 | Acute Myeloid Leukemia; Glioblastoma; Locally Advanced Pancreatic Adenocarcinoma; Recurrent Lung Small Cell Carcinoma … | Nov 2026 |
| Daewoong Pharmaceutical | Olaparib (DWZ2501) PARP 1, 2 and 3 inhibitor | PARP1, PARP3, PARP2 | Phase 1 | Cancer | Mar 2027 |
| Boryung Pharmaceutical | Olaparib (BR2022) PARP 1, 2 and 3 inhibitor | PARP1, PARP3, PARP2 | Phase 1 | Ovarian Cancer | – |
Ovarian Cancer (11) Breast Cancer (9) Acute Myeloid Leukemia (8) Advanced Malignant Solid Neoplasm (7) Prostate Cancer (6) Metastatic Castration-resistant Prostate Cancer (4) Solid Tumor (4) Glioma (3) Metastatic Malignant Solid Neoplasm (3) Lung Cancer (3) Cancer (3) Solid Tumors (2)
small molecule (6), mixed (3)
AstraZeneca (1) Merck & Co. (MSD) (1) National Cancer Institute (NCI) (1) pharmaand (1) The Netherlands Cancer Institute (1) Alliance for Clinical Trials in Oncology (1) Boryung Pharmaceutical (1) M.D. Anderson Cancer Center (1) Daewoong Pharmaceutical (1)
PARP1 (9) PARP2 (9) CHRNB2 (1) CHRNA4 (1) Tubulin (1) OPRM1 (1) CD274 (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.